Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders

TL;DR

This review discusses rare plasma cell disorders, their challenges in diagnosis and treatment, and the need for better strategies to manage these complex conditions.

Contribution

The paper provides a comprehensive synthesis of current knowledge and challenges in diagnosing and treating rare plasma cell disorders.

Findings

Rare plasma cell disorders are biologically diverse and often aggressive, making diagnosis and treatment difficult.

Improved outcomes have been seen with proteasome inhibitors and immunomodulatory agents in some subtypes.

Standardized diagnostic criteria and clinical trials are needed to address ongoing challenges in management.

Abstract

Rare plasma cell disorders—including IgD, IgE, and IgM multiple myeloma, non-secretory myeloma (NSMM), plasma cell leukemia (PCL), and heavy chain disease (HCD)—are biologically heterogeneous and often present with atypical features and aggressive behavior. This review synthesizes current evidence on their epidemiology, pathophysiology, diagnosis, and treatment. Advances in proteasome inhibitors, immunomodulatory agents, and autologous transplantation have improved outcomes in select subtypes. However, challenges persist in distinguishing IgM myeloma from Waldenström macroglobulinemia, monitoring non-secretory disease, and treating highly aggressive forms such as IgE myeloma and PCL. Standardized diagnostic criteria and prospective trials are essential to guide future management.